CA3135712A1 - Process for preparing xpo1 inhibitors and intermediates for use in the preparation of xp01 inhibitors - Google Patents
Process for preparing xpo1 inhibitors and intermediates for use in the preparation of xp01 inhibitors Download PDFInfo
- Publication number
- CA3135712A1 CA3135712A1 CA3135712A CA3135712A CA3135712A1 CA 3135712 A1 CA3135712 A1 CA 3135712A1 CA 3135712 A CA3135712 A CA 3135712A CA 3135712 A CA3135712 A CA 3135712A CA 3135712 A1 CA3135712 A1 CA 3135712A1
- Authority
- CA
- Canada
- Prior art keywords
- structural formula
- compound represented
- conditions suitable
- produce
- represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962841649P | 2019-05-01 | 2019-05-01 | |
| US62/841,649 | 2019-05-01 | ||
| PCT/US2020/031124 WO2020223678A1 (en) | 2019-05-01 | 2020-05-01 | Process for preparing xpo1 inhibitors and intermediates for use in the preparation of xp01 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3135712A1 true CA3135712A1 (en) | 2020-11-05 |
Family
ID=70802955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3135712A Pending CA3135712A1 (en) | 2019-05-01 | 2020-05-01 | Process for preparing xpo1 inhibitors and intermediates for use in the preparation of xp01 inhibitors |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12479806B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3962898A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7630444B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220004142A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114040909B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020266170B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021021706A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3135712A1 (cg-RX-API-DMAC7.html) |
| CR (1) | CR20210590A (cg-RX-API-DMAC7.html) |
| IL (1) | IL287673B1 (cg-RX-API-DMAC7.html) |
| MA (1) | MA55808A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021013211A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202111993SA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020223678A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114040909B (zh) | 2019-05-01 | 2025-06-03 | 卡尔约药物治疗公司 | 用于制备xpo1抑制剂以及用于制备xp01抑制剂的中间体的方法 |
| JP2021048976A (ja) * | 2019-09-24 | 2021-04-01 | 株式会社ユニバーサルエンターテインメント | 遊技機 |
| CN112679477B (zh) * | 2020-12-17 | 2021-10-26 | 佛山奕安赛医药科技有限公司 | 塞利尼索及其中间体的制备方法 |
| CN116514773B (zh) * | 2023-04-24 | 2024-12-03 | 重庆汉佩生物科技有限公司 | 一种Verdinexor(KPT-335)及其盐酸盐的合成方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2542089B1 (en) | 2010-03-05 | 2017-01-18 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
| EP2665362B1 (en) | 2011-01-17 | 2016-03-30 | Karyopharm Therapeutics, Inc. | Olefin containing nuclear transport modulators and uses thereof |
| EP4234545A3 (en) | 2011-07-29 | 2023-09-06 | Karyopharm Therapeutics Inc. | Hydrazide containing nuclear transport modulators and uses thereof |
| JP6006794B2 (ja) | 2011-07-29 | 2016-10-12 | カリオファーム セラピューティクス，インコーポレイテッド | 核内輸送調節因子およびその使用 |
| WO2013170068A2 (en) * | 2012-05-09 | 2013-11-14 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
| EP2968278B8 (en) | 2013-03-15 | 2019-05-22 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using crm1 inhibitors |
| WO2014205393A1 (en) | 2013-06-21 | 2014-12-24 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| ME03421B (me) | 2013-06-21 | 2020-01-20 | Karyopharm Therapeutics Inc | 1,2,4-triazoli kao modulatori nuklearnog transporta i njihova upotreba |
| KR102608259B1 (ko) | 2014-08-15 | 2023-11-29 | 카리오팜 쎄라퓨틱스, 인코포레이티드 | 셀리넥소의 다형태 |
| US10526295B2 (en) | 2015-12-31 | 2020-01-07 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| EP3397634A1 (en) | 2015-12-31 | 2018-11-07 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
| WO2017118940A1 (en) * | 2016-01-08 | 2017-07-13 | Dr. Reddy's Laboratories Limited | Solid forms of selinexor and process for their preparation |
| EP3565813A1 (en) * | 2017-01-05 | 2019-11-13 | Watson Laboratories, Inc. | Novel crystalline forms of selinexor and process for their preparation |
| CN114040909B (zh) | 2019-05-01 | 2025-06-03 | 卡尔约药物治疗公司 | 用于制备xpo1抑制剂以及用于制备xp01抑制剂的中间体的方法 |
-
2020
- 2020-05-01 CN CN202080048243.6A patent/CN114040909B/zh active Active
- 2020-05-01 AU AU2020266170A patent/AU2020266170B2/en active Active
- 2020-05-01 SG SG11202111993SA patent/SG11202111993SA/en unknown
- 2020-05-01 BR BR112021021706A patent/BR112021021706A2/pt unknown
- 2020-05-01 MX MX2021013211A patent/MX2021013211A/es unknown
- 2020-05-01 WO PCT/US2020/031124 patent/WO2020223678A1/en not_active Ceased
- 2020-05-01 CA CA3135712A patent/CA3135712A1/en active Pending
- 2020-05-01 MA MA055808A patent/MA55808A/fr unknown
- 2020-05-01 US US17/607,670 patent/US12479806B2/en active Active
- 2020-05-01 CR CR20210590A patent/CR20210590A/es unknown
- 2020-05-01 KR KR1020217038842A patent/KR20220004142A/ko active Pending
- 2020-05-01 JP JP2021564434A patent/JP7630444B2/ja active Active
- 2020-05-01 EP EP20727786.4A patent/EP3962898A1/en active Pending
-
2021
- 2021-10-28 IL IL287673A patent/IL287673B1/en unknown
-
2025
- 2025-02-04 JP JP2025016855A patent/JP7850834B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020266170A1 (en) | 2021-11-25 |
| US20220242832A1 (en) | 2022-08-04 |
| CR20210590A (es) | 2022-03-11 |
| JP2025072490A (ja) | 2025-05-09 |
| JP2022531576A (ja) | 2022-07-07 |
| JP7850834B2 (ja) | 2026-04-23 |
| WO2020223678A1 (en) | 2020-11-05 |
| US12479806B2 (en) | 2025-11-25 |
| MX2021013211A (es) | 2022-03-11 |
| SG11202111993SA (en) | 2021-11-29 |
| IL287673B1 (en) | 2026-01-01 |
| EP3962898A1 (en) | 2022-03-09 |
| MA55808A (fr) | 2022-03-09 |
| JP7630444B2 (ja) | 2025-02-17 |
| CN114040909A (zh) | 2022-02-11 |
| IL287673A (en) | 2021-12-01 |
| BR112021021706A2 (pt) | 2022-04-19 |
| KR20220004142A (ko) | 2022-01-11 |
| AU2020266170B2 (en) | 2026-02-26 |
| CN114040909B (zh) | 2025-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12479806B2 (en) | Process for preparing XPO1 inhibitors and intermediates for use in the preparation of XPO1 inhibitors | |
| JP6439050B2 (ja) | Ａｓｋ１阻害剤を調製するプロセス | |
| EP3645518B1 (en) | Synthesis of omecamtiv mecarbil | |
| JP6873053B2 (ja) | タンパク質脱アセチル化阻害剤の製造方法 | |
| JP2014509642A (ja) | イマチニブ及びそのメシル酸塩の生成のための改良方法 | |
| CN112047888A (zh) | 一种合成恩杂鲁胺的方法 | |
| KR20230004622A (ko) | 모노아실글리세롤 리파제 억제제의 합성 | |
| JP2012025705A (ja) | （ｓ）−４−〔（４−クロロフェニル）（２−ピリジル）メトキシ〕ピペリジンのジアステレオマー塩の製造方法 | |
| WO2021225956A1 (en) | Methods for synthesizing anhydrous lactic acid | |
| JP7406692B2 (ja) | 可溶性グアニル酸シクラーゼ刺激薬を調製するための方法 | |
| CA2840806A1 (en) | Novel salts of sitagliptin | |
| JP2009525964A (ja) | ６，７−ジヒドロ−５Ｈ−イミダゾ［１，２−ａ］イミダゾール−３−スルホン酸アミドの合成 | |
| JP5078211B2 (ja) | 複素環式化合物の製造方法 | |
| JP2023542365A (ja) | タウロデオキシコール酸ナトリウムの大量生産方法 | |
| CN114436991A (zh) | 一种2-氨基噻唑类化合物的合成方法 | |
| IL280312B2 (en) | Process for the preparation of bromodomain inhibitor | |
| CN115368283A (zh) | 一种手性结构或非手性结构的顺式-3-氟-4-羟基吡咯烷及其衍生物的制备方法 | |
| EP0379423B1 (fr) | Nouveau procédé d'obtention d'un acide phénylpropionique | |
| HK40068051B (en) | Synthesis of omecamtiv mecarbil | |
| HK40068051A (en) | Synthesis of omecamtiv mecarbil | |
| WO2022239735A1 (ja) | アピキサバンの精製方法 | |
| JPH09216886A (ja) | トリアゾロピリダジン誘導体の製造法 | |
| HK40025477A (en) | Synthesis of omecamtiv mecarbil | |
| HK40025477B (en) | Synthesis of omecamtiv mecarbil | |
| JP2012197254A (ja) | ベンジル２−ハロエチルカルバメートの製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220728 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240807 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241206 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250205 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250502 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250502 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250627 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250627 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251114 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251117 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251128 |